Additional file 2: of Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia
- Masayuki Shirasawa (6404960)
- Tomoya Fukui (3225930)
- Seiichiro Kusuhara (6404966)
- Yasuhiro Hiyoshi (3551315)
- Yoshiro Nakahara (394606)
- Noriko Nishinarita (6404975)
- Satoshi Igawa (2082046)
- Katsuhiko Naoki (4051669)
Publication date
February 2019
DOIAbstract
Figure S2. KaplanâMeier analyses of overall survival (OS) of ED-SCLC patients treated with chemotherapy. Blue: Patients without IP who did not develop AE-IP; Red: Patients with IP who did not develop AE-IP; Orange: Patients who developed AE-IP; and Green: the OS of ED-SCLC patients who received the best supportive care (BSC) only. The number of individuals in each group and median survival time (95% CI) are indicated. (PPTX 52 kb
Add to ORKG